<DOC>
	<DOCNO>NCT01723228</DOCNO>
	<brief_summary>This 24-week , multicenter , randomize , double-blind , placebo-controlled , add-on , parallel-group study evaluate effect rasagiline cognitive function adult mild cognitive impairment ( MCI ) Parkinson 's disease ( PD-MCI ) .</brief_summary>
	<brief_title>Parallel-Group Study Assess Effect Rasagiline Cognition Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>1 . Nondemented man woman 45 80 year age idiopathic Parkinson 's disease ( PD ) base United Kingdom ( UK ) Parkinson 's Disease Society Brain Bank Clinical Diagnostic Criteria 2 . Hoehn Yahr stage ≥ 1 ( symptom 1 side body ) treatment ≤ 3 ( mildtomoderate bilateral disease ; postural instability ; physically independent ) 3 . Mild cognitive impairment Parkinson 's disease base Movement Disorder Society ( MDS ) Task Force Diagnostic Criteria Montreal Cognitive Assessment ( MoCA ) rating scale ( range , 2025 , inclusive ) 4 . Medically stable outpatient , base investigator 's judgment 5 . The patient stable dopaminergic medication regimen ≥ 30 day enter study ( Screening/Baseline Visit ) 6 . Other inclusion criterion apply ; please contact site information 1 . Clinically relevant history vascular disease ( eg , stroke ) 2 . History melanoma 3 . History deep brain stimulation ( DBS ) 4 . Impaired hepatic function , base investigator 's judgment 5 . Psychosis receive antipsychotic treatment 6 . Clinically significant unstable medical surgical condition may preclude safe complete study participation , base investigator 's judgment 7 . Other exclusion criterion apply ; please contact site information</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Cognition</keyword>
	<keyword>Rasagiline</keyword>
</DOC>